Quantcast
Channel: cirrhosis – BioTuesdays
Browsing latest articles
Browse All 10 View Live

Image may be NSFW.
Clik here to view.

Galectin targets silent epidemic in liver fibrosis

Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). Dr. Peter...

View Article



Image may be NSFW.
Clik here to view.

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...

View Article

Image may be NSFW.
Clik here to view.

Ciclofilin demonstrates anti-fibrotic activity with CPI-431-32

Closely-held Ciclofilin Pharmaceuticals’ lead antiviral drug has demonstrated anti-fibrotic activity in a liver fibrosis animal model. CPI-431-32 is a proprietary cyclophilin antagonist that potently...

View Article

Image may be NSFW.
Clik here to view.

In conversation with Geoffrey Hamilton-Fairley

Mr. Hamilton-Fairley As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the...

View Article

Image may be NSFW.
Clik here to view.

Can-Fite gets FDA fast track for liver cancer drug

The FDA has granted Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, fast track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of...

View Article


Image may be NSFW.
Clik here to view.

HCW starts Galectin Therapeutics at buy

H.C. Wainwright has initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and 12-month price target of $7. The stock closed at $2.28 on Friday. Galectin is a clinical-stage...

View Article

Image may be NSFW.
Clik here to view.

Leerink starts Tobira Therapeutics at outperform

Leerink Partners has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with an “outperform” rating and $24 price target in 12 months. The stock closed at $9.26 on Thursday. Tobira is aiming to...

View Article

Image may be NSFW.
Clik here to view.

Can-Fite expands development of CF102 into NASH

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded...

View Article


Image may be NSFW.
Clik here to view.

HCW starts Tobira Therapeutics at buy

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday. Tobira is focused on the development of a sole...

View Article


Image may be NSFW.
Clik here to view.

Galectin completes patient recruitment in NASH trial

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX...

View Article
Browsing latest articles
Browse All 10 View Live




Latest Images